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1. ABSTRACT 
 
Alzheimer's disease is a multifactorial and 
progressive neurodegenerative disease, extremely diffused 
and with an increasing prevalence worldwide. There is an 
urgent need for biomarkers to diagnose AD early in its 
course. Furthermore, accurate biomarkers would be able to 
determine the clinical efficacy of novel neuroprotective 
strategies.  Although the heritability of late-onset AD is 
high, our knowledge of the underlying putative 
susceptibility genes remains incomplete and the only 
unequivocally established late-onset AD gene is APOE. 
Nevertheless a number of susceptibility loci seems to 
influence the pathogenesis of AD, and variations in 
numerous genes have been considered to be important in 
the risk for AD. Many advances have been made in 
identifying biochemical indices of brain dysfunction, 
measured in body fluids such as cerebrospinal fluid and 
plasma, with different methodological approaches. 
Although these biomarkers are promising, none of them 
can predict AD with 100% confidence to date. This review 
will elaborate on the available selection of genetic and 
biochemical biomarkers for AD, with a particular reference 
to those linked to inflammation and oxidative stress.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. INTRODUCTION 
 
Alzheimer's disease (AD) is a heterogeneous and 
progressive neurodegenerative disease which in Western 
society mainly accounts for clinical dementia. 
Neurodegeneration in AD appears to be multifactorial, 
whereby several biochemical processes operate 
sequentially and/or in parallel. Neuro-pathological 
hallmarks are senile plaques, resulting from the 
accumulation of several proteins and an inflammatory 
reaction around deposits of amyloid, a fibrillar protein, 
Abeta, product of cleavage of a much larger protein, the 
beta-amyloid precursor protein (APP) and neurofibrillary 
tangles. Amyloid deposition, due to the accumulation of 
Abeta peptide, is the main pathogenetic mechanism. It is 
quite clear that similar or identical pathological lesions can 
be the consequence of multiple environmental and genetic 
susceptibility factors, and thus, the initial causative 
biological processes may differ between the affected 
individuals. The pathological process characteristic of AD 
begins decades before the first symptoms of brain failure, 
thus making it difficult to reliably identify pathology based 
on the clinical phenotype alone. The increasing prevalence 
of AD motivate the drive to develop diagnostic biomarkers 
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to reliably identify the pathology at an early stage. 
Although many neurodegenerative diseases cannot be cured 
at the present time, there are often symptomatic treatments 
available and new drugs are emerging to forestall and/or 
reverse the onset and/or progress of the diseases (1, 2). 
Thus, an early diagnosis will at least assist in the better 
management of patient care. Biomarkers for AD may also 
help to identify subclasses of the disorders, monitoring of 
disease progression and treatment (3). Advances have been 
made in neuroimaging techniques that assess regional 
structure, function and biochemistry of the brain, as well as 
in identifying biochemical indices of brain dysfunction, 
measured in body fluids such as cerebrospinal fluid (CSF) 
and plasma (4). This review will elaborate on the available 
selection of genetic and biochemical biomarkers for AD, 
with a particular reference to those linked to inflammation 
and oxidative stress, since the review is mostly focused on 
data from author laboratories. 
 
3. PATHOGENESIS OF AD 
 
 Amongst the existing entities of dementia 
spectrums, Alzheimer’s disease and dementia with vascular 
component are the most prevalent forms of dementia. 
These disorders have common and unique molecular 
pathological characteristics that result in serious reductions 
in nervous-system functionality (5). AD, the most common 
cause of dementia, accounts for 50 to 70 percent of 
dementia cases (6). It is a severe neurodegenerative 
disorder characterized by progressive memory and 
cognitive impairment. The multiple pathogenic events in 
AD can be classified as primary events (genetic factors, 
neuronal apoptosis), secondary events (beta-amyloid 
(Abeta) deposition in senile plaques and brain vessels, 
neurofibrillary tangles due to hyperphosphorylation of tau 
proteins, synaptic loss), tertiary events (neurotransmitter 
deficits, neurotrophic alterations, neuroimmune 
dysfunction, neuroinflammatoray reactions) and quaternary 
events (excitotoxic reactions, calcium homeostasis 
miscarriage, free radical formation, primary and/or reactive 
cerebrovascular dysfunction) (7). Under physiological 
conditions, APP is processed by the non-amyloidogenic 
pathway, where cleavage by alfa-secretase releases a 
soluble fragment. In AD, this process is significantly 
altered, where increased amount of APP is cleaved by other 
endo-proteases such as beta- and gamma-secretase, 
generating highly amyloidogenic beta-amyloid protein 
molecules of 40-42 amino acid residues. Soluble beta-
amyloid protein rapidly aggregates into fibrils triggering 
the misfolding of other Abeta species. In vitro studies have 
shown that extracellular fibrillar Abeta peptides induce 
apoptosis in cultured neurons (8). The amyloid cascade 
hypothesis is the central hypothesis for the cause of AD, 
which states that the initiating event in AD is an imbalance 
between the production and clearance of Abeta in the brain 
(9). Another neuropathological hallmark of AD is the 
appearance of neurofibrillary tangles that consist of a 
hyperphosphorylated form of the microtubule-stabilizing 
protein tau, often conjugated with ubiquitin. The abnormal 
hyperphosphorylation of tau makes it resistant to 
proteolysis and this might lead to several-fold increase in 
the levels of tau in AD. The hyperphosphorylated tau 
causes sequestration of normal tau and other microtubule-
associated proteins, leading to inhibition and disruption of 
microtubules and impaired axonal transport (10). Tau also 
becomes prone to aggregation leading to formation of 
intracellular neurofibrillary tangles, compromising 
neuronal and synaptic function. A recent study has 
suggested a link between amyloid and neurofibrillary 
tangles, whereby Abeta exposure triggers caspase cleavage 
of tau, which in turn promotes the assembly of tau into 
pathological filaments (11). Several other hypotheses have 
been proposed to explain the pathogenesis of AD, including 
abnormalities in proteins regulating the cell cycle, 
inflammatory mechanisms, oxidative stress, and 
mitochondrial dysfunction with disruption in neuronal 
energy metabolism. In particular generation of reactive 
oxygen species (ROS) and/or reactive nitrogen species 
(RNS) associated with mitochondrial dysfunction have 
been demonstrated to play an essential role in the 
pathogenesis of this disease  (12).   
 
4. GENETIC OF ALZHEIMER’S DISEASE 
 
Although the complete etiopathogenesis of AD 
still remains unclear, genetic studies over the past two 
decades have provided valuable insights into this complex 
and heterogeneous disorder. Twin and family studies have 
shown that certain genes contribute to the development of 
AD, especially with respect to the age at which the disease 
manifests, and more recently, the development of non-
cognitive symptomatology (13). Early onset familial AD is 
a very rare autosomal dominant disorder caused by highly 
penetrant mutations in APP and presenilin genes, both 
linked to Abeta metabolism. Around twelve different 
mutations have been identified in APP gene at the level of 
alfa-,beta-, or gamma-secretase cleavage sites, which can 
lead to alteration in the normal proteolysis of amyloid 
precursor protein. Similarly, more than fifthly missense 
mutations of the presenilin-1 gene (PS1) are associated 
with familial AD; several mutations of presnilin-2 gene 
(PS2) are associated with rare cases of early onset familial 
AD (14). These mutations of APP, PS1 and PS2 may share 
a common pathogenetic mechanism leading to 
accumulation of beta-amyloid protein as a result of 
abnormal amyloid precursor protein metabolism. In 
contrast, sporadic AD is a very common disorder. Although 
the heritability of late-onset AD is high, our knowledge of 
the underlying putative susceptibility genes remains 
incomplete. The only unequivocally established late-onset 
AD gene is APOE (OMIM 107741), encoding 
apolipoprotein E, a protein involved in the transport of 
cholesterol. Three apoE gene alleles are described (epsilon 
2, epsilon 3, and epsilon 4). A growing volume of evidence 
has reported an association of apoE epsilon 4, late-onset 
familial, and sporadic AD (15).  
 
 ε4 allele increases the risk for AD by 4- to 15-
fold in a dosedependent manner, and epsilon 2 has shown a 
protective effect. As many as 40 to 50% of AD patients 
possess ε4 allele compared to 15 to 25% of controls. 
Subjects homozygous for epsilon 4 are reported to have a 
6- to 8-fold increased risk of developing AD compared to 
the risk of heterozygotic subjects (increased by 2- to 4-
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fold). Moreover, APOE epsilon 4 may influence AD 
pathology by  interacting with APP metabolism and β-
amyloid protein accumulation, enhancing  
hyperphosphorylation of tau protein and neurofibrillary 
tangle formation, reducing choline acetyltransferase 
activity, increasing oxidative processes, modifying 
inflammation-related neuroimmunotrophic activity and 
glial activation, altering lipid metabolism, lipid transport 
and membrane biosynthesis in sprouting and synaptic 
remodelling, and inducing neuronal apoptosis. To date, no 
other late onset AD gene has been conclusively proven, 
nevertheless a number of susceptibility loci seems to 
influence the pathogenesis of AD. Several studies have 
reported susceptibility loci on chromosome 1, 2, 5, 9, 10, 
12, 14, 18, 19 (close to ApoE), and 21 (close to the APP 
gene) (16, 17). Genomewide association analyses of AD 
reported evidence of an association between variants in 
GRB2-associated binding protein 2 (Gab2) (OMIM 
606203) on chromosome 11q14 and AD risk (18). Gab2 is 
a member of a family of evolutionarily highly conserved 
scaffolding and adapter proteins that are involved in 
multiple signalling pathways and particularly in the 
transduction of cytokine and growth receptor signalling 
(19). Gab2 is ubiquitously expressed but is found at high 
levels in white blood cells, prefrontal cortex, and 
hypothalamus (20). Changes in Gab2 expression could 
potentially affect Gsk3-dependent phosphorylation of tau 
and the formation of neurofibrillary tangles (21). Moreover, 
growth factor receptor–bound protein 2, which binds Gab2, 
has been reported to bind tau, APP, and presenilin 1 and 2, 
giving sense for the involvement of this gene in the 
pathogenesis of AD (22).  Furthermore GAB2 effect sizes 
are among the strongest and most significant observed in 
any putative disease gene after APOE in the field of AD. 
Variations in inflammation and apoptosis genes, such as 
HLA-A2, interleukins (IL1A, IL1B, and IL6) and tumor 
necrosis factor-alpha (TNF) have also been considered to 
be important in the risk for AD (23, 24). Other 
polymorphisms that may also be associated with AD are 
linked to the angiotensin-converting enzyme, Cystatin C, 
tau genes, estrogen receptor and 5-lipoxygenase enzyme. 
Genes involved in the neurodevelopmental process have 
also been considered good candidates to confer 
susceptibility to AD. All these genetic factors may interact 
in unknown genetic networks leading to a cascade of 
pathogenic events characterized by abnormal protein 
folding, with subsequent accumulation of abnormal 
proteins, ubiquitin-proteosome system dysfunction, 
exicitotoxic reactions, oxidative stress, mitochondrial 
injury, synaptic failure, altered metal homeostasis, axonal 
and dendritic transport dysfunction and chaperone 
misoperation. In particular, cytokine gene polymorphisms 
have been claimed to play a key role in pathophysiology of 
AD. Several studies report associations between IL-1beta 
polymorphisms and AD, but findings from different studies 
are controversial. We have recently performed a meta-
analysis to verify the correlation between the single 
nucleotide polymorphisms (SNPs) of the IL-1beta, at sites -
511 and +3953, and AD (25). The results support an 
association between the TT genotype of IL-1beta +3953 
SNP and AD, and suggest a possible association of the -511 
TT genotype. 
5. BIOCHEMICAL MARKERS 
 
The biochemical markers of AD can be classified 
as primary (specific), such as Abeta or Tau, or secondary to 
the disease, or they can simply be epiphenomenal in nature. 
A wide variety of different proteins such as inflammatory 
markers, markers of oxidative stress, apolipoproteins, and 
markers of neuronal degeneration in blood and 
cerebrospinal fluid have been examined. The cerebrospinal 
fluid has been the principal focus of research for diagnostic 
markers in AD pathology due to its direct contact with the 
extracellular space of the brain (26), and the quantification 
of tau and Abeta in the CSF represent the most intensively 
studied biomarkers of AD (27). Approximately 80% of 
patients who meet clinical criteria for AD have elevated 
levels of CSF tau. The relationship between high levels of 
CSF tau and a pathologic diagnosis of AD has been 
confirmed also in autopsy studies (28). High CSF total tau 
(t-tau) has been proposed as a marker able to discriminate 
between memory-impaired individuals that later progressed 
to AD, and those that did not convert (29). Other authors 
have shown that the absolute level of CSF tau in patients 
with AD did not correlate with the severity or duration of 
the dementia (30). Another line of recent evidence suggests 
that CSF phosphotau (tau protein phosphorylated at 
threonine 231) declines during the natural course of AD. In 
this study the authors demonstrated that CSF phosphotau 
concentration, but not total tau, decreased over time in AD, 
independent of age. Rate of change was inversely 
correlated to cognitive decline, suggesting that CSF 
phosphotau may have the potential to track AD 
progression.  
 
Aβ (1-42) is especially prone to fibrillization and 
disproportionally accumulates in extracellular lesions in 
AD brains, and most studies showed that Abeta 1-42 
concentrations are lower in the CSF of AD patients. 
Decrease in CSF Abeta 1-42 in AD is probably the most 
consistent BM finding, and has been hypothesized to reflect 
a deposition of the peptide in senile plaques, with lower 
levels diffusing to the CSF. Abeta 1-42 alone showed a 
sensitivity of 78%, and a specificity of 81%, in 
distinguishing AD patients from elderly controls (32). 
However, studies correlating CSF Abeta  1-42 protein 
concentrations with cognitive performance in AD were, in 
part, contradictory (33) and the potential value of Abeta 1-
42 protein during the course of AD progression should be 
further evaluated. Plasma Abeta 1-40 and Abeta 1-42 levels 
did not correlate with the disease (34), and results from 
different studies are often conflicting (35). A recent 
research conducted in presymptomatic familial AD persons 
indicated that plasma Abeta 1-42 is elevated in familial AD 
mutations carriers and that this level may decrease with the 
cognitive decline of disease progression prior to the 
development of dementia (36). Looking for secondary 
markers, advanced proteomic approach has provided 
numerous potential biomarkers to differentiate AD from 
non-AD with high sensitivity and specificity (for a review 
see 37 ). Using LC–MS platform, a recent research has 
revealed more than 100 candidate markers, including brain-
derived neurotrophic factor (BDNF), interleukin (IL)-8, 
vitamin D binding protein (VDBP), apolipoprotein (apo) 
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AII, and apoE, as potential CSF biomarkers for AD (38). In 
a more recent SELDI-TOF-MS study, 15 potential 
biomarkers were identified and a panel of five markers 
(Cystatin C, truncated Cystatin C, Abeta1–40, C3a 
anaphylatoxin des-Arg and a 4.0 kDa protein) togetherwith 
total tau and Abeta1–42 analysis could distinguish AD 
from healthy control individuals with high sensitivity and 
specificity (39). Finally, because blood is more easily 
accessible than CSF, a search is also underway for useful 
plasma biomarkers in AD. A recent research has 
demonstrated increased concentrations of complement 
factor H and alfa-2-macroglobulin (40), while another 
study identified four potential biomarker peaks using the 
serumalbumin-bound fraction from AD and control 
subjects (41).  
 
 It is widely believed that Abeta deposition in 
the brain starts an immune reaction leading to the 
development of the local chronic reaction typical of AD. 
Recently, our group has reported data on immune-
inflammatory parameters evaluated in PBMC obtained 
from AD patients (42). We showed no changes in 
lymphocytes subsets with the exclusion of B cells that are 
reduced in AD subjects. The study of B cell naïve/memory 
compartment shows a reduction of DN (IgD-CD27-) B 
cells in AD patients compared with age-matched healthy 
controls. Inflammatory cytokines IL-1beta, IL-6, IFN-
gamma, TNF-alfa, chemokines MIP-1beta and RANTES as 
well as chemokines receptors CCR2, CCR3 and CCR5, are 
up-regulated in AD patients after in vitro stimulation with 
amyloid-beta (rAbeta42) peptide.  
 
 Also CD36, a scavenger receptor, is over-
expressed in monocytes of AD patients. All together these 
data confirm the involvement of systemic immunity in AD 
and suggest to continue these kind of study to obtain 
biomarkers useful in the  monitoring the effectiveness of 
therapeutics. 
 
Fibroblasts of sporadic AD patients represent another 
important starting point in the research for novel 
biomarkers because of their various abnormalities in 
metabolic and biochemical processes, which reflect some 
of the events in the AD brain (43). A recent research has 
demonstrated an abnormal response of AD fibroblasts to an 
acute oxidative injury; in particular, fibroblasts from AD 
patients were found to be less vulnerable to the oxidative 
injury induced by H2O2 in comparison with fibroblasts 
from non-AD subjects (44). The tumor suppressor and 
transcription factor p53 plays a pivotal function in neuronal 
apoptosis triggered by oxidative stress. On the basis of 
immunoprecipitation studies with conformation-specific 
p53 antibodies, which discriminated folded vs. unfolded 
p53 tertiary structure, it has been found that in fibroblasts 
from AD patients a significant amount of total p53 assumes 
an unfolded tertiary structure in comparison with 
fibroblasts from control elderly subjects (45). In addition 
and most importantly,  another research (46)  has proposed 
a rapid, easy and quantitative flow cytometric approach for 
the discrimination of conformational mutant p53-bearing 
cells from AD patients compared to non-AD controls, using 
small volumes of blood. Using this technique, they 
processed 75 AD, 66 controls, 15 subjects affected by 
another neuroinflammatory disease, Parkinson’s disease 
and 3 subjects affected with other types of dementia (2 
vascular dementia; 1 progressive supranuclear palsy) and 
confirmed the previous findings: AD subjects expressed 
higher levels of unfolded p53 in comparison with controls 
and subjects with other neurological diseases. Within this 
specific age interval (< 70 years), a comparison of the 
sensitivity and specificity values of this approach with 
those published in several studies, which evaluated the 
diagnostic power of CSF markers for AD (Total-tau, 
Phosphotau and Abeta 1-42), reveal that p53 measurement 
is more sensitive (90% compared to respectively 81.4%, 
81.3% and 85.9%), but less specific (77% compared to 
respectively 91.5%, 91.2% and 88.5%). On the whole, 
these data strongly suggest that the measurement of 
conformational altered p53 in blood cells has a high ability 
to ddiscriminate AD cases from normal ageing, Parkinson’s 
disease and other dementias (47). 
 
 Additionally biomarkers could also be 
identified in human brain tissues. It has been observed that 
in AD frontal cortex autopsies protein kinase C (PKC) 
translocation is blunted when compared to age-matched 
controls (48) and this can be correlated with a defective 
expression of RACK1 levels (49), underscoring an 
alteration in PKC signal transduction in human brain under 
conditions of memory impairment. From a pharmacological 
perspective in animal models of AD, activation of brain 
PKC (such as with bryostatin-1) can influence beta amyloid 
deposition and clearance (50) and counteract behavioral 
deficits. The possibility to utilize PKC as a potential AD 
biomarker is encouraged by the fact that changes in PKC 
signal transduction are reported also in peripheral tissues 
such as fibroblasts and lymphocytes from AD patients (for 
a review see 51).  Studies have applied proteomic 
technologies to characterize specific proteins in AD brain, 
for example, using redox proteomics (a branch of 
proteomics that identifies oxidativelymodified proteins) a 
number of proteins that are oxidatively modified in AD 
brain have been identified (52, 53). Cortical and 
hippocampal oxidative stress is a very early event in the 
pathogenesis of sporadic AD and correlates with the 
development of specific cognitive deficits in this condition. 
Heat shock proteins have been regarded as cytoprotectants 
that protect brain cells from damage encountered following 
cerebral ischemia or during the progression of 
neurodegenerative diseases. Heme oxygenase-1 (HO-1) is a 
32-kDa stress protein that catalyzes the degradation of 
heme to biliverdin. Increased expression of HO-1 is a 
common feature in a number of neurodegenerative diseases 
(54). The HO-1 gene is redox regulated and its activation 
could represent a protective system potentially active 
against brain oxidative injury (55). HO-1 has been also 
proposed as a potential biomarker for AD, and its 
expression in AD patients brain is significantly increased 
(56).  Interestingly, the spatial distribution of HO-1 
expression in diseased brain is essentially identical to that 
of pathological expression of tau (57). HO-1 
immunoreactivity is greatly increased in neurons and 
astrocytes of the hippocampus and cerebral cortex of 
individuals with AD and colocalizes to senile plaques and 
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neurofibrillary tangles. HO-1 is thought to  down regulate 
the production of tau and recently HO-1 polymorphisms 
have been considered as a possible responsible for 
susceptibility to AD (58). Plasma and CSF HO-1 protein 
and lymphocyte HO-1 mRNA levels have been 
demonstrated to decrease in subjects with sporadic AD, 
compared to normal elderly controls and non AD 
neurologic patients (59). In particular the sensitivity and 
specificity of lymphocyte HO-1 mRNA measurement for 
diagnosis of early sporadic AD presented in this study are 
88% and 75% (60). 
 
6. CONCLUSIVE REMARKS 
 
Several experimental methods have been used to 
identify single biomarkers in early disease stage of AD. 
Although these biomarkers are promising, none of them 
can predict AD with 100% confidence nor provide a clear 
delineation of subgroups at risk and thus, a combination of 
markers may be necessary. This seems difficult, especially 
because they are costly, invasive, or unsuitable for broad 
application. Nevertheless, there is an urgent need for 
biomarkers to diagnose AD early in its course, to 
differentiate it from other related diseases or subtypes. 
Furthermore, accurate biomarkers would be able to 
determine the clinical efficacy of novel neuroprotective 
strategies. With improved experimental design/sample 
preparation and implementation of advanced 
methodologies and analysis tools researches in biomarkers 
for AD will likely contribute significantly to managing this 
neurodegenerative disease in the years to come. 
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